CAPTEM or FOLFIRI as SEcond-line Therapy in NEuroendocrine CArcinomas
about
CAPTEM or FOLFIRI as SEcond-line Therapy in NEuroendocrine CArcinomas
description
clinical trial
@en
klinisch onderzoek
@nl
name
CAPTEM or FOLFIRI as SEcond-line Therapy in NEuroendocrine CArcinomas
@en
type
label
CAPTEM or FOLFIRI as SEcond-line Therapy in NEuroendocrine CArcinomas
@en
prefLabel
CAPTEM or FOLFIRI as SEcond-line Therapy in NEuroendocrine CArcinomas
@en
P4844
P6153
P1050
P1476
A Randomized Phase II Trial of ...... Imaging and Biological Markers
@en
P17
P1813
SENECA
@en
P3098
NCT03387592
P580
2017-03-06T00:00:00Z
P582
2021-01-01T00:00:00Z